東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Next Generation kinase inhibitors = ...

Shapiro, Paul.

Linked to FindBook

Google Book

Amazon

博客來

Next Generation kinase inhibitors = moving beyond the ATP binding/catalytic sites /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Next Generation kinase inhibitors/ edited by Paul Shapiro.
Reminder of title:	moving beyond the ATP binding/catalytic sites /
other author:	Shapiro, Paul.
Published:	Cham :Springer International Publishing : : 2020.,
Description:	xii, 217 p. :ill., digital ;24 cm.
[NT 15003449]:	Chapter 1: Introduction to Kinases, Cellular Signaling, and Kinase Inhibitors -- Chapter 2: Overview of Current Type I/II Kinase Inhibitors -- Chapter 3: Avoiding or Co-opting ATP Inhibition: Type III, IV, V, and VI Kinase Inhibitors -- Chapter 4: Structural Features Regulating Kinase Interactions with Regulatory and Substrate Proteins -- Chapter 5: Developing Kinase Inhibitors using Computer-Aided Drug Design Approaches -- Chapter 6: A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition -- Chapter 7: Novel Stabilized Peptide Inhibitors of Protein Kinases -- Chapter 8: Novel peptide-based inhibitors of protein kinases -- Index.
Contained By:	Springer Nature eBook
Subject:	Protein kinases - Inhibitors. -
Online resource:	https://doi.org/10.1007/978-3-030-48283-1
ISBN:	9783030482831

Next Generation kinase inhibitors = moving beyond the ATP binding/catalytic sites /
Next Generation kinase inhibitorsmoving beyond the ATP binding/catalytic sites /[electronic resource] :edited by Paul Shapiro. - Cham :Springer International Publishing :2020. - xii, 217 p. :ill., digital ;24 cm.

Chapter 1: Introduction to Kinases, Cellular Signaling, and Kinase Inhibitors -- Chapter 2: Overview of Current Type I/II Kinase Inhibitors -- Chapter 3: Avoiding or Co-opting ATP Inhibition: Type III, IV, V, and VI Kinase Inhibitors -- Chapter 4: Structural Features Regulating Kinase Interactions with Regulatory and Substrate Proteins -- Chapter 5: Developing Kinase Inhibitors using Computer-Aided Drug Design Approaches -- Chapter 6: A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition -- Chapter 7: Novel Stabilized Peptide Inhibitors of Protein Kinases -- Chapter 8: Novel peptide-based inhibitors of protein kinases -- Index.

Protein kinases are fascinating enzymes that maintain the proper function of nearly every task performed by the cells of the human body. By extracting a phosphate from the energy molecule ATP and linking it to another protein, protein kinases alter the structure and ultimate function of other proteins. In this way, protein kinases help monitor the extracellular environment and integrate signaling cues that, for the most part, are beneficial for human health and survival. However, protein kinases are often dysregulated and responsible for the initiation and progression of many types of cancers, inflammatory disorders, and other diseases. Thus, decades of research have revealed much about how protein kinases are regulated and approaches to inhibit these enzymes to treat disease. However, nearly 30 years since the identification of the first clinically beneficial small molecule protein kinase inhibitor, there are only a few examples where these drugs provide sustained and durable patient responses. The goal of this book is to provide biomedical scientists, graduate, and professional degree students insight into different approaches using small molecules to block specific protein kinase functions that promote disease.

ISBN: 9783030482831

Standard No.: 10.1007/978-3-030-48283-1doiSubjects--Topical Terms:

3460770
Protein kinases
--Inhibitors.

LC Class. No.: QP606.P76 / N498 2020

Dewey Class. No.: 572.792

Next Generation kinase inhibitors = moving beyond the ATP binding/catalytic sites /
LDR:02939nmm a2200325 a 4500 001 2222210
003 DE-He213
005 20201106144245.0
006 m d
007 cr nn 008maaau
008 210108s2020 sz s 0 eng d
020 $a 9783030482831 $q (electronic bk.)
020 $a 9783030482824 $q (paper)
024 7 $a 10.1007/978-3-030-48283-1 $2 doi
035 $a 978-3-030-48283-1
040 $a GP $c GP
041 0 $a eng
050 4 $a QP606.P76 $b N498 2020
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 572.792 $2 23
090 $a QP606.P76 $b N567 2020
245 0 0 $a Next Generation kinase inhibitors $h [electronic resource] : $b moving beyond the ATP binding/catalytic sites / $c edited by Paul Shapiro.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xii, 217 p. : $b ill., digital ; $c 24 cm.
505 0 $a Chapter 1: Introduction to Kinases, Cellular Signaling, and Kinase Inhibitors -- Chapter 2: Overview of Current Type I/II Kinase Inhibitors -- Chapter 3: Avoiding or Co-opting ATP Inhibition: Type III, IV, V, and VI Kinase Inhibitors -- Chapter 4: Structural Features Regulating Kinase Interactions with Regulatory and Substrate Proteins -- Chapter 5: Developing Kinase Inhibitors using Computer-Aided Drug Design Approaches -- Chapter 6: A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition -- Chapter 7: Novel Stabilized Peptide Inhibitors of Protein Kinases -- Chapter 8: Novel peptide-based inhibitors of protein kinases -- Index.
520 $a Protein kinases are fascinating enzymes that maintain the proper function of nearly every task performed by the cells of the human body. By extracting a phosphate from the energy molecule ATP and linking it to another protein, protein kinases alter the structure and ultimate function of other proteins. In this way, protein kinases help monitor the extracellular environment and integrate signaling cues that, for the most part, are beneficial for human health and survival. However, protein kinases are often dysregulated and responsible for the initiation and progression of many types of cancers, inflammatory disorders, and other diseases. Thus, decades of research have revealed much about how protein kinases are regulated and approaches to inhibit these enzymes to treat disease. However, nearly 30 years since the identification of the first clinically beneficial small molecule protein kinase inhibitor, there are only a few examples where these drugs provide sustained and durable patient responses. The goal of this book is to provide biomedical scientists, graduate, and professional degree students insight into different approaches using small molecules to block specific protein kinase functions that promote disease.
650 0 $a Protein kinases $x Inhibitors. $3 3460770
650 1 4 $a Cancer Research. $3 891172
700 1 $a Shapiro, Paul. $3 3460769
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-48283-1
950 $a Biomedical and Life Sciences (SpringerNature-11642)